CHGCY

Chugai Pharmaceutical Co., Ltd. [CHGCY] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

CHGCY Stock Summary

Top 10 Correlated ETFs

CHGCY

Top 10 Correlated Stocks

CHGCY

In the News

CHGCY Financial details

Company Rating
-
Market Cap
54.49B
Income
325.47B
Revenue
1111.37B
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
7.6K
Optionable
No
Shortable
Yes
Earnings
25 Apr 2024
P/E
27.05
Forward P/E
-
PEG
-20.66
P/S
7.14
P/B
5.93
P/C
-
P/FCF
47.77
Quick Ratio
3.54
Current Ratio
4.76
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
197.83
EPS next Y
-
EPS next Q
-
EPS this Y
-13.1%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
15.57%
Revenue last 5Y
10.12%
Revenue Q/Q
6.17%
EPS Q/Q
17.56%
-
-
-
-
SMA20
-3.95%
SMA50
5.67%
SMA100
-2.95%
Inst Own
-
Inst Trans
-
ROA
19%
ROE
23%
ROC
0.3%
Gross Margin
58%
Oper. Margin
37%
Profit Margin
26%
Payout
39%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
11.93-22.61
52W High
+4.68%
52W Low
+109.36%
RSI
51.59
Rel Volume
0.26
Avg Volume
154.08K
Volume
40.14K
Perf Week
3%
Perf Month
-8.94%
Perf Quarter
-2.58%
Perf Half Y
-5.96%
-
-
-
-
Beta
0.469
-
-
Volatility
0.42%, 0.76%
Prev Close
5.21%
Price
23.03
Change
8.89%

Something similar

Top by Market Cap
AMZN
META
AAPL
MIX.JO
VTI
Top Correlated ETFs
CONL
FBL
META
AGOX
WEBL
Top Correlated Stocks
BBAI
ACXP
BKSY
WIX
0HC3.L
Similar Market Cap
014790.KS
1808.TW
0384.HK
4820.T
HMT.NS

Company Profile

Healthcare Drug Manufacturers - General
  • Volume Average 154.08K
  • Market Capitalization 54.49B
  • Employee 7.6K
  • CEO Dr. Osamu Okuda
  • Headquarters Tokyo,JP
  • IPO Date 2012-08-03
  • Website https://www.chugai-pharm.co.jp

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and neurology/other diseases comprise Hemlibra, CellCept, and Enspryng. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.